These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Oncolytic viruses-immunotherapeutics on the rise. Keller BA; Bell JC J Mol Med (Berl); 2016 Sep; 94(9):979-91. PubMed ID: 27492706 [TBL] [Abstract][Full Text] [Related]
6. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109 [TBL] [Abstract][Full Text] [Related]
8. Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. Elia AR; Grioni M; Basso V; Curnis F; Freschi M; Corti A; Mondino A; Bellone M Clin Cancer Res; 2018 May; 24(9):2171-2181. PubMed ID: 29490991 [No Abstract] [Full Text] [Related]
9. Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma. Majd N; de Groot J Expert Opin Pharmacother; 2019 Sep; 20(13):1609-1624. PubMed ID: 31264484 [No Abstract] [Full Text] [Related]
10. Glioblastoma Therapy in the Age of Molecular Medicine. Geraldo LHM; Garcia C; da Fonseca ACC; Dubois LGF; de Sampaio E Spohr TCL; Matias D; de Camargo Magalhães ES; do Amaral RF; da Rosa BG; Grimaldi I; Leser FS; Janeiro JM; Macharia L; Wanjiru C; Pereira CM; Moura-Neto V; Freitas C; Lima FRS Trends Cancer; 2019 Jan; 5(1):46-65. PubMed ID: 30616755 [TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for Glioblastoma: Adoptive T-cell Strategies. Choi BD; Maus MV; June CH; Sampson JH Clin Cancer Res; 2019 Apr; 25(7):2042-2048. PubMed ID: 30446589 [TBL] [Abstract][Full Text] [Related]
12. Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic Virotherapy. Rojas JJ; Sampath P; Hou W; Thorne SH Clin Cancer Res; 2015 Dec; 21(24):5543-51. PubMed ID: 26187615 [TBL] [Abstract][Full Text] [Related]
13. Oncolytic Viruses as a Platform for the Treatment of Malignant Brain Tumors. Sostoa J; Dutoit V; Migliorini D Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33050329 [TBL] [Abstract][Full Text] [Related]
14. Development of oncolytic virotherapy: from genetic modification to combination therapy. Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606 [TBL] [Abstract][Full Text] [Related]
15. CAR T cells and checkpoint inhibition for the treatment of glioblastoma. Shen SH; Woroniecka K; Barbour AB; Fecci PE; Sanchez-Perez L; Sampson JH Expert Opin Biol Ther; 2020 Jun; 20(6):579-591. PubMed ID: 32027536 [No Abstract] [Full Text] [Related]
16. Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds. Asija S; Chatterjee A; Yadav S; Chekuri G; Karulkar A; Jaiswal AK; Goda JS; Purwar R Int Rev Immunol; 2022; 41(6):582-605. PubMed ID: 35938932 [TBL] [Abstract][Full Text] [Related]
17. Immunostimulatory bacterial antigen-armed oncolytic measles virotherapy significantly increases the potency of anti-PD1 checkpoint therapy. Panagioti E; Kurokawa C; Viker K; Ammayappan A; Anderson SK; Sotiriou S; Chatzopoulos K; Ayasoufi K; Johnson AJ; Iankov ID; Galanis E J Clin Invest; 2021 Jul; 131(13):. PubMed ID: 34196308 [TBL] [Abstract][Full Text] [Related]
18. Combinatorial Effects of VEGFR Kinase Inhibitor Axitinib and Oncolytic Virotherapy in Mouse and Human Glioblastoma Stem-Like Cell Models. Saha D; Wakimoto H; Peters CW; Antoszczyk SJ; Rabkin SD; Martuza RL Clin Cancer Res; 2018 Jul; 24(14):3409-3422. PubMed ID: 29599413 [No Abstract] [Full Text] [Related]
19. Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma. Tang B; Guo ZS; Bartlett DL; Yan DZ; Schane CP; Thomas DL; Liu J; McFadden G; Shisler JL; Roy EJ Clin Cancer Res; 2020 May; 26(9):2216-2230. PubMed ID: 32019860 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy. Rezaei R; Esmaeili Gouvarchin Ghaleh H; Farzanehpour M; Dorostkar R; Ranjbar R; Bolandian M; Mirzaei Nodooshan M; Ghorbani Alvanegh A Cancer Gene Ther; 2022 Jun; 29(6):647-660. PubMed ID: 34158626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]